Cerebrolysin after stroke: read the outcomes carefully
AXON Research Institute • AXON Peptide affiliation
Educational draft • Scientific + legal review pending
Silent film with full on-screen captions. Conceptual illustrations, not molecular structures.

For stroke research, the outcome you measure can change the headline. Cerebrolysin is a peptide mixture studied as an additional treatment. A 2023 Cochrane review found no convincing survival benefit and a possible increase in nonfatal serious adverse events. Those findings deserve attention. A later review reported improvement in early neurological scores. Different trial selections and endpoints help explain why the summaries differ; they do not settle every recovery question. Cerebrolysin is not FDA-approved in the United States. It should never be presented as a replacement for urgent stroke care or evidence-based rehabilitation.

END CARD
Evidence first. Educational only. Sources in description.

SOURCES
[1] Cerebrolysin for acute ischaemic stroke: 2023 Cochrane review
https://doi.org/10.1002/14651858.CD007026.pub7
Authoritative systematic review of randomized human trials

[2] Safety and Efficacy of Cerebrolysin for Neurorecovery After Acute Ischemic Stroke: Meta-Analysis of 14 RCTs
https://pmc.ncbi.nlm.nih.gov/articles/PMC12465088/
Later peer-reviewed systematic review; different inclusion criteria and outcomes

[3] Cerebrolysin official product site: US regulatory disclosure
https://www.cerebrolysin.com/cerebrolysin/about-cerebrolysin
Manufacturer used only for explicit US nonapproval disclosure, not efficacy claims

EVIDENCE LIMITATIONS
Present both the Cochrane safety signal and later efficacy synthesis fairly.
Do not describe mixed evidence as proof of regeneration, stroke reversal or guaranteed independence.
Industry funding, trial bias and outcome reporting require scrutiny.

TOPIC INVENTORY PROVENANCE (not reused audiovisual media)
https://www.facebook.com/reel/1267672258858231/